Arrowhead completes enrollment in phase 1 study of ARO-AAT for treatment of liver disease
Arrowhead Pharma announced it has completed enrollment of a Phase 1 clinical study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference therapeutic being developed as treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency. June 18, 2018